HALO - Halozyme Therapeutics Inc

HALO - Halozyme Therapeutics Inc

https://halozyme.com

Momentum: Bearish

Recent News

Powered by Alpha Vantage

Are You Looking for a Top Momentum Pick? Why Halozyme Therapeutics ( HALO ) is a Great Choice

Zacks Commentary • 1 week, 5 days ago • score: 0.50

Does Halozyme Therapeutics (HALO) have what it takes to be a top stock pick for momentum investors? Let's find out.

Best Momentum Stock to Buy for September 3rd

Zacks Commentary • 1 week, 5 days ago • score: 0.46

HALO, TROW and CARS made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on September 3, 2025.

Are Medical Stocks Lagging Halozyme Therapeutics ( HALO ) This Year?

Zacks Commentary • 1 week, 5 days ago • score: 0.35

Here is how Halozyme Therapeutics (HALO) and atai Life Sciences N.V. (ATAI) have performed compared to their sector so far this year.

Halozyme Therapeutics, Inc. ( HALO ) Hit a 52 Week High, Can the Run Continue?

Zacks Commentary • 1 week, 5 days ago • score: 0.46

Halozyme Therapeutics (HALO) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

New Strong Buy Stocks for September 3rd

Zacks Commentary • 1 week, 5 days ago • score: 0.12

TDW, JRVR, HALO, SCSC and CSW have been added to the Zacks Rank #1 (Strong Buy) List on September 3, 2025.

Here's How Much a $1000 Investment in Halozyme Therapeutics Made 10 Years Ago Would Be Worth Today

Zacks Commentary • 1 week, 6 days ago • score: 0.33

Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

Source: Snapshot

Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company is headquartered in San Diego, California.

52W High

$75.46

52W Low

$42.01

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

1.20

Valuation

Attractive

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

17.15

Forward P/E (<15 better)

9.12

EV/EBITDA (<8 favorable)

12.28

EV/Revenue (<3 favorable)

8.25

P/S (TTM) (<3 favorable)

7.44

P/B (<3 favorable)

26.34

Ownership

Institution‑heavy

Source: Overview

Insiders (1–5% typical)

1.17%

Institutions (25–75% balanced)

102.68%

Shares Outstanding

116,966,000

Float

115,516,000

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

1,178,672,000

Gross Profit (TTM)

913,381,000

EPS (TTM)

4.37

Profit Margin (>10% good)

0.47%

Operating Margin (TTM) (higher better)

0.62%

ROE (TTM) (>15% strong)

1.79%

EPS YoY (Quarterly) (>10% good)

0.85

Revenue YoY (Quarterly) (>8% good)

0.41

Momentum

Bearish momentum

Value

3.9941

Previous

4.0738

Trend

Falling

Signal Cross

No cross

As of

Sep. 12, 2025